Ra Medical Systems Announces Granting of New US Patent
Ra Medical Systems (NYSE American: RMED) announced the granting of a new patent (number D980,420 S) by the USPTO on March 7, 2023, for its VIVO product's technology.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ra Medical Systems (NYSE American: RMED) announced the granting of a new patent (number D980,420 S) by the USPTO on March 7, 2023, for its VIVO product's technology. This patent enhances the company's intellectual property portfolio, which now includes 36 issued patents and 15 applications related to electrophysiology products, alongside 15 additional licensed patents for VIVO technology. The VIVO system is a non-invasive 3D imaging solution that helps identify the origins of ventricular arrhythmias, thus improving workflow efficiency and reducing procedure duration. Executive Chairman David Jenkins emphasized the strategic importance of IP for the company’s future value.
Positive
- Issuance of new patent (D980,420 S) strengthens RMED's IP portfolio.
- Total of 36 issued patents and 15 applications for electrophysiology products.
- 15 patents licensed into the company for VIVO technology.
- Enhanced technology for VIVO improves workflow and procedure efficiency.
Negative
- None.
Details
News Market Reaction – RMED
The recorded move for RMED in the trading session of this news was -4.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FORT MILL, SC / ACCESSWIRE / March 9, 2022 / Ra Medical Systems, Inc. (NYSE American:RMED) today announced that it has been notified of a new patent granted by the USPTO covering technology utilized in its VIVO product. The patent, number D980,420 S, entitled "Kit of Positioning Patches", was issued on March 7, 2023. The patent covers technology used in the disposable components of the VIVO product.
 logo-1.png)
David Jenkins, Executive Chairman of RMED, commented, "This newly issued patent joins a robust estate of intellectual property accumulated by our company. For the electrophysiology products, we have now have 36 issued patents and 15 application in process. Additionally, we have 15 patents and patent applications licensed into the company covering the VIVO technology. As a small medical device technology company, we believe the obtaining of IP is critical to our future and to the value of our company. We are quite pleased that another US patent has been granted to us."
About VIVO
Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.
About Ra Medical Systems
Ra Medical, and its wholly owned subsidiary Catheter Precision, is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
CONTACTS:
At the Company
David Jenkins
973-691-2000
mhuck@catheterprecision.com
SOURCE: Ra Medical
View source version on accesswire.com:
https://www.accesswire.com/742976/Ra-Medical-Systems-Announces-Granting-of-New-US-Patent
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.